Parameters | Values |
Age |
|
Median (range) | 52 [26 - 83] |
WHO PSa |
|
0 | 47 (35.4%) |
1 | 78 (58.6%) |
2 | 8 (6%) |
Histological subtype |
|
SCCb | 122 (91.7%) |
Adenocarcinoma | 8 (6%) |
Others | 3 (2.3%) |
Tumor size |
|
Median (range) | 6 [3 - 13] |
RLNc metastasis |
|
Absence | 73 (54.9%) |
Pelvic only | 46 (34.6%) |
Lombo-aortic +/− Pelvic | 14 (10.5%) |
FIGO stage |
|
I-II | 49 (36.8%) |
III-IVA | 84 (63.2%) |
Hbd level |
|
Median (range) | 11.2 [3.9 - 15.5] |
Total dose to the tumor |
|
Mean (range) | 69.6 [66-70] |
Use of concurrent chemotherapy |
|
Yes | 126 (94.7%) |
No | 7 (5.3%) |
Overall treatment time (in days) |
|
Median | 60 [49 - 109] |
Response to treatment (at the first follow-up visit) |
|
Complete | 107 (80.5%) |
Partial | 18 (13.5%) |
Progression | 8 (6%) |